Close Menu

InDevR

The certification comes ahead of the company's planned launch of a microarray-based test for differentiating seasonal and non-seasonal influenza viruses.

St. Jude's Richard Webby will assess the performance of InDevR's FluChip-8G test on non-seasonal influenza viruses.

Agilent Technologies this week announced updates to its SurePrint miRNA Microarrays to include targets from the latest version of the miRBase public miRNA database.

NEW YORK (GenomeWeb) — Researchers at Johns Hopkins University have performed the first validation of the Cepheid Xpert Flu assay in a population of emergency room patients with acute undifferentiated respiratory illness.

NEW YORK (GenomeWeb) – By the end of 2016, InDevr aims to have a microarray-based clinical test on the market for genotyping influenza viruses.

NEW YORK (GenomeWeb) – InDevr announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority to finish the development of a microarray-based test for influenza.

Applied Microarrays and InDevR this week announced a new partnership that will pair AMI's contract array manufacturing resources with InDevR's instrumentation and assay development capabilities.

NEW YORK (GenomeWeb) – InDevR and Applied Microarrays said today that they will work together to offer custom microarrays, instruments, and reagents for multiplexed assays.

Indevr recently launched its AmpliPhox system for nucleic acid and protein microarray analysis.

Pages

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.